Speaker illustration

Professor Erland Erdmann

University of Cologne, Cologne (Germany)

Member of:

European Society of Cardiology

My main scientific interests are pathophysiology and treatment options of heart failure as well as the role of diabetes in cardiovascular disease. I have served in the steering committees of several major international drug and device trials directed to improve cardiovascular diseases such as CIBIS I, II and III, CARE-HF, PROACTIVE, SERVE-HF (all of which have been published in NEJM or The Lancet). Until 2017 I was editor of the main German textbook of cardiology (Klinische Kardiologie) now in the 8th edition, Furthermore I was editor of several international scientific journals.

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure<sup> </sup>

Date: 9 July 2012

Journal: European Heart Journal

Thumbnail

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

Date: 1 January 2008

Journal: European Heart Journal

Thumbnail